Document:

ex102.htm

SERVICE SOFTWARE PROVIDER AGREEMENT

THIS SERVICE SOFTWARE PROVIDER AGREEMENT (the “Agreement”) is made this April 14, 2014 by and between PANASH S.A.C. (hereinafter referred to as "THE PROVIDER") a Peruvian corporation whose place of business is 730 Larco Avenue, Apartment 302, Miraflores District, Lima-Peru, represented by Mr. Rafael Quispe Calagua and TRUPAL MEDIA, INC (hereinafter referred to as "THE COMPANY") whose place of business is located at 1205 Lincoln Road, Suite 220, Miami Beach, Florida 33139, represented by Panayis Palexas.

RECITALS

WHEREAS, THE PROVIDER is a social media services provides as well as software developer, online services integrator and complete marketing services provider; and

WHEREAS TRUPAL MEDIA, INC is a social media publisher and gaming business developer.

AGREEMENT

In this context, the parties shall comply with the following Terms of Use:

	
I.  

	
SCOPE OF SERVICE:

THE COMPANY wishes to utilize the services of THE PROVIDER to develop creative ads, manage its social networks, maintain and engage existing users via social networks, creative posting and managing of its Facebook Fan page. Ensuring brand positioning whilst growing awareness, user growth and retention.

	
II.  

	
ACCESS:

The access is subject exclusively to these Terms and Conditions and the parties will not use the Website for any purpose that is unlawful or prohibited by these Terms and Conditions.

	
III.  

	
COMPENSATION:

The PROVIDER will be paid by the COMPANY for its services with a minimum of $10,000 (Ten Thousand US dollars) monthly or 10% of monthly revenue earned by the app the PROVIDER is servicing. This amount will not exceed $100,000 per month. Only in the 1st year of operation accumulated compensation can be paid with a Promissory Note which will coming to effect before the end of April 2016.

  

Page 1 of 6

  

	
IV.  

	
TAXES:

Each party will be responsible for all taxes and expenses associated with the execution of this agreement.

	
V.  

	
INTELLECTUAL PROPERTY:

All copyright, trademarks and all other intellectual property rights in the app, website, products and its content (including without Iimitation the Website design, text, graphics and all software and source codes connected with the Website) are owned by THE COMPANY.

	
VI.  

	
TERM

The term of this agreement will be for three (3) years and can be extended by the agreement of both parties, in writing.

	
VII.  

	
LIABILITY

Nothing in this Agreement shall exclude or restrict liability for fraud, or death or personal injury resulting from the negligence of either party or their agents or employees.

Neither party shall be liable to the other for any indirect, consequential or special damages or loss of profits or any other pure economic loss arising out of or in connection with this Agreement.

	
VIII.  

	
CONFIDENTIALITY

	
a.  

	
“Confidential Information” means any and all information whether commercial or technical related to the business of The Company, including know-how, data, processes, designs, photographs, drawings, specifications, software programs, and samples, which is marked with an indicator such as “Confidential” or “Proprietary”, but excluding information which:

	
i.  

	
is or comes into the public domain otherwise than by disclosure or default by The Company;

	
ii.  

	
was or is lawfully obtained or available from a third party who was or is lawfully in possession of the same and free to disclose it; or

	
iii.  

	
was already known evidenced by written record pre-dating such disclosure.

  

Page 2 of 6

  

	
b.  

	
In consideration of The Company disclosing Proprietary Information, THE DEVELOPER hereby undertakes for a period of five (05) years from the date of this Agreement:

	
i.  

	
Keep confidential all Proprietary Information that it may acquire in any manner;

	
ii.  

	
Use such Proprietary Information exclusively for the Permitted Purpose and not to use the Proprietary Information for the Developer’s own purposes or benefit;

	
iii.  

	
Inform everybody to whom it discloses Proprietary Information that it is confidential and obtain their agreement to keep it confidential on the same terms as this Agreement;

	
iv.  

	
Keep safe any drawings, documents, samples or materials provided on loan by The Company, not to reproduce, part with possession of, modify or otherwise interfere with such items, to return them immediately upon The Company’s request and in any event spontaneously when no longer required for the purposes of this Agreement;

	
v.  

	
Notify the Company immediately upon becoming aware of any breach of confidence by anybody to whom the DEVELOPER has disclosed the Information and give all necessary assistance in connection with any steps which The Company wish to prevent, stop or obtain compensation for such breach or threatened breach.

	
c.  

	
Nothing in this Agreement shall be deemed to grant to the Company a licence expressly or by implication under any patent, copyright or other intellectual property right.  All intellectual property rights relating to any drawings, documents and work carried out by the DEVELOPER (whether past, present or future) using the Proprietary Information will belong to and will vest in The Company.  The DEVELOPER will do all such things and execute all documents necessary to enable The Company to obtain, defend or enforce its rights in such drawings, documents and work.

	
IX.  

	
NOTICES

Any notice required or permitted to be given pursuant to this Agreement shall be sent or delivered to the other party as follows:

To the PROVIDER at:

730 Larco Avenue

Department 302

Miraflores District

Lima-Peru

Fax: + 51 (01) 399-0730

  

Page 3 of 6

  

To the COMPANY at:

1205 Lincoln road, Suite 220

Miami Beach, Florida, 33139

All notices which are permitted or required to be given hereunder shall be in writing and shall be sent to the address of the recipient set out above in this Agreement or such other address as the recipient may designate by notice given in accordance with the provisions of this clause. Any such notice may be delivered personally, or by courier or registered post, or by first class pre-paid letter, or by facsimile transmission and shall be deemed to have been served when delivered if delivered by hand, if by first class post seven days after posting, and if by facsimile transmission supported by printed confirmation report when dispatched, and if by courier or registered post when signed for.

 

	
X.  

	
GOVERNING LAW

This agreement shall be governed by and construed in accordance with the laws of the State of Florida, USA.

Any action or proceeding in connection with this agreement shall be brought before a competent court in Florida USA, provided that, at the option of the COMPANY, any such proceeding may also be brought before any other competent court.

  

Page 4 of 6

  

 

 

PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGE TO FOLLOW

 

 

 

  

Page 5 of 6

  

IN WITNESS WHEREOF, the Parties have executed this Agreement through their respective duly authorized officers as of the date first above written.

	
Panash S.A.C.

 

	 	
Trupal Media, Inc.

 

	
By:/s/ Mr. Rafael Quispe Calagua

	 	
By:/s/ Panayis Palexis

	
Mr. Rafael Quispe Calagua

	 	
Panayis Palexis

	
Representative

	 	
CEO

  

Page 6 of 6Exhibit 10.2

 

AMENDED AND RESTATED PATENT LICENSE
AGREEMENT

 

BETWEEN 

 

THE BOARD OF REGENTS OF THE UNIVERSITY
OF TEXAS SYSTEM 

 

AND 

 

PLX PHARMA INC.

 

DATED December
11, 2009

 

     

     

    

 

TABLE OF
CONTENTS

 

	1. EFFECTIVE DATE	3
	2. DEFINITIONS	4
	3. WARRANTY: SUPERIOR RIGHTS	6
	4. LICENSE	7
	5. PAYMENTS AND REPORTS	9
	6. COMMON STOCK: EQUITY OWNERSHIP AND PLX BOARD
    RIGHTS	12 
	7. TERM AND TERMINATION	12 
	8. INFRINGEMENT	14 
	9. ASSIGNMENT	15 
	10. PATENT MARKING AND MAINTENANCE	15 
	11. INDEMNIFICATION	15 
	12. USE OF BOARD AND UTHSC-H NAME	15 
	13. CONFIDENTIAL INFORMATION AND PUBLICATION	16 
	14. PATENTS AND INVENTIONS	16 
	15. ALTERNATE DISPUTE RESOLUTION	17 
	16. GENERAL	18 

 

     

     

    

 

AMENDED
AND RESTATED PATENT LICENSE AGREEMENT

 

THIS AGREEMENT (“Agreement”)
is between the Board of Regents (“Board”)
of The University of Texas System (“System”),
an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas
Health Science Center at Houston (“UTHSC-H”), a component institution of System and PLx
Pharma Inc., a Texas corporation (“PLx”),
with its principal place of business at 8285 El Rio, Suite 130, Houston, Texas 77054. Board, UTHSC-H, and PLx may
individually be referred to as Party or collectively as the Parties.

 

RECITALS

 

A.          Board
owns certain Patent Rights and Technology
Rights related to Licensed Subject Matter, which
were developed at The University of Texas Health Science Center at Houston (“UTHSC-H”),
a component institution of System.

 

B.          Board
desires to have the Licensed Subject Matter
developed in the Licensed Field and used for the benefit
of PLx, the Inventor,
Board, and the public as outlined in Board’s
Intellectual Property Policy.

 

C.           PLx
desires to obtain a license from Board to Commercialize
Licensed Subject Matter.

 

D.          Board and GrassRoots
Pharmaceuticals Inc. entered into a license agreement dated January 8, 2003, which Original Agreement was amended by: the
Amendment to Patent License Agreement effective July 2003; the Second Amendment to Patent License Agreement effective November
5, 2003; the Third Amendment to Patent License Agreement effective April 15, 2004; the Fourth Amendment to Patent License Agreement
effective April 30, 2004; the Fifth Amendment to Patent License Agreement effective April 7, 2005; the Sixth Amendment to Patent
License Agreement effective May 3, 2006; and the Seventh Amendment to Patent License Agreement effective June 26, 2007, (collectively
the “Original Agreement”)

 

E.           GrassRoots Pharmaceuticals’
Board of Directors consented to changing its name to PLx Pharma Inc. on March 20, 2003, and filed its name change with the Office
of the Secretary of State of Texas on April 10, 2003.

 

F.            The
parties hereby desire to amend and restate the Original Agreement as set forth below. 

 

NOW,
THEREFORE, in consideration of the mutual covenants and
premises herein contained, the parties agree as follows:

 

1.  EFFECTIVE
DATE

 

This Agreement
is effective December 11, 2009 (“Effective Date”).

 

    	 	3	 

     

    

 

2.  DEFINITIONS

 

As used in this Agreement,
the following terms have the meanings indicated:

 

		2.1	“Actively
Attempting to Commercialize” means

 

		a.	having an effective, ongoing and
                                         active research, development, manufacturing, marketing or sales program as appropriate,
                                         directed toward obtaining regulatory approval, production, or Sales
                                         of Licensed Products
                                         or Sales
                                         of a product incorporating Licensed
                                         Products or a part thereof, , in any jurisdiction, and where PLx
                                         has provided plans reasonably acceptable to UTHSC-H,
                                         to Commercialize Licensed
                                         Subject Matter in Licensed
                                         Territory; or

 

		b.	having at least one Licensed
                                         Product currently being reviewed as an IND
                                         or NDA
                                         or the equivalent thereof by a Regulatory
                                         Authority.

 

2.2         “Additional Patent Rights” means Board’s
rights in inventions or discoveries covered by patent(s) or patent applications, whether domestic or foreign, within
the Licensed Field resulting and constituting an
Improvement.

 

		2.3	“Affiliate”
means:

 

		i)	any business entity at least 50% owned
                                         by PLx, or any
                                         business entity that owns at least 50% of PLx;

 

		ii)	any business entity that is at least
                                         50% owned by a business entity that owns at least 50% of PLx;
                                         or

 

		iii)	any business entity in which PLx
                                         has a controlling share.

 

2.4        
“Commercialize” means having Sales
of Licensed Products, Sales
of products incorporating Licensed Products
or parts thereof.

 

2.5        
“Improvements” means any modification or further
development of the Patent Rights or
Technology Rights that are:

 

		i)	within the Licensed
                                         Field; and

 

		ii)	made by solely by Inventor
                                         at UTHSC-H; and

 

		iii)	made during the term of, and in
                                         the scope and performance of a Sponsored
                                         Research Agreement.

 

2.6        
“IND” means an Investigational New Drug application
or a Treatment Investigational New Drug application submitted to the FDA
for a Licensed Product under 21 C.F.R. Part
312 or a comparable application submitted to another Regulatory Authority.

 

2.7        
“Inventor” means Dr. Lenard Lichtenberger or
any person specifically under Dr. Lichtenberger’s supervision in his capacity as a principal investigator of research in
the Licensed Field at UTHSC-H.
For clarity, Inventor shall not include persons employed by another employer or System institution, or researchers
at UTHSC-H that are not under Dr. Lichtenberger’s supervision.

 

    	 	4	 

     

    

 

2.8         “Licensed Field” means a pharmacological composition
comprising a phospholipid(s) and an anti-inflammatory agent, for medical and veterinary use. Licensed
Field shall not include (U.S. patent numbers 6,943,155 and 7354912) or any of Board’s
rights necessary for practicing such patents.

 

2.9         “Licensed Product” means any product or service
comprising or derived from Licensed Subject Matter or any
equipment or product with which Licensed Subject Matter
is combined, attached, packaged, retrofitted, marketed, or Sold
by PLx and/or its Affiliates.

 

2.10        “Licensed Subject Matter” means inventions
and discoveries by Inventor covered by Patent Rights, or
Additional Patent Rights or
Technology Rights.

 

2.11        “Licensed Territory” means worldwide.

 

2.12       “NDA” means a New Drug Application or an Abbreviated
New Drug Application submitted to the FDA for a Licensed
Product under 21 C.F.R. Part 314 or a comparable application submitted to another Regulatory
Authority.

 

2.13       “Net Sales”
means the gross revenues received by PLx and its Affiliates,
subsidiaries, or Sublicensees, as the case may be, from the Sale
of Licensed Products, less:
sales and use taxes actually paid, import and export duties actually paid, unreimbursed outbound transportation
prepaid or allowed, and amounts allowed or credited due to returns (not to exceed the original billing or invoice amount).

 

2.14       “Patent Rights” means Board’s
rights in inventions or discoveries covered by patent(s) or patent applications, whether domestic or foreign, listed
in Attachment A, and any patent(s) issuing from the applications, and all divisionals, continuations, reissues, revival, reexaminations
or extensions thereof within the
Licensed Field.

 

2.15       “Phase I Clinical Trials” means investigational
use of a Licensed Product for determining metabolic and
pharmacologic actions in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on
effectiveness, under 21 C.F.R. Part 312 or comparable laws, rules, or regulations of another Regulatory
Authority.

 

2.16       “Phase II Clinical Trials” means investigational
use of a Licensed Product for examining the suspected indication(s)
and to determine potential short-term side effects in humans, under 21 C.F.R. Part 312 or comparable laws, rules, or regulations
of another Regulatory Authority.

 

2.17       “Phase III Clinical Trials” means investigational
use of a Licensed Product for establishing its safety,
efficacy, labeled indications, and risk–benefit profile in humans, under 21 C.F.R. Part 312 or comparable laws, rules, or
regulations of another Regulatory Authority.

 

    	 	5	 

     

    

 

2.18       “Regulatory Authority” means the Food and Drug
Administration of the United States of America (“FDA”)
or any comparable agency in a country outside the United States of America that is authorized to regulate the licensure, approval,
manufacture, and sale of pharmaceuticals, biologics, dietary supplements, medical foods, nutriceuticals, food additives, cosmetics,
diagnostics, medical devices, and medical processes.

 

2.19       “Sale, Sold or Sell” means the transfer or
disposition of a Licensed Product for value to a party
other than PLx or Affiliate.

 

2.20       “Shareholders Agreement” means, as subsequently amended, the Amended and Restated Shareholders Agreement, dated
April 30, 2004, by and among PLx and certain of its shareholders.

 

2.21       “Sponsored Research Agreement” means any sponsored research agreement between UTHSC-H
and PLx in effect during the
term of during this Agreement,
where Dr. Lichtenberger is the principal investigator, and that specifically
refers to this Agreement for the clarification of rights related to the Improvements or Licensed Subject
Matter.

 

2.22       “Technology Rights” means Board’s
rights in technical information, know-how, processes, procedures, compositions, devices, methods, formulas, protocols,
patterns, compilations, programs, products, techniques, data, preparations, usage information, trade secrets, drawings or data:

 

(a) are developed
or created by solely by Inventor at UTHSC-H,
whether or not patentable; and

 

(b) are
not covered by Patent Rights or Additional
Patent Rights, but are necessary for practicing Patent
Rights or Additional Patent Rights.

 

3.  WARRANTY: SUPERIOR RIGHTS

 

3.1          Except
for the rights, if any, of the Government of the United States, as set forth below, Board
represents and warrants its belief that (i) it is the owner of the entire right, title, and interest in and to Licensed
Subject Matter, (ii) it has the right to grant licenses thereunder, and (iii) it has not knowingly granted licenses
thereunder to any other entity that would restrict rights granted to PLx
except as stated herein.

 

3.2          PLx
understands that the Licensed Subject Matter
was developed under a funding agreement with the Government of the United States of America and that the Government may have certain
rights relative thereto. This Agreement is explicitly made
subject to the Government’s rights under any agreement and any applicable law or regulation. If there is a conflict between
any such agreement or applicable law or regulation and this Agreement,
the terms of the Government agreement or applicable law or regulation shall prevail.

 

    	 	6	 

     

    

 

 

3.3          PLx
understands and acknowledges that Board, by
this Agreement, makes no representation as to the operability
or fitness for any use, safety, efficacy, ability to obtain regulatory approval, patentability, or breadth of the Licensed
Subject Matter. Board, by this Agreement,
also makes no representation as to whether there are any patents now held, or that will be held, by others or by Board
in the Licensed Field, nor does Board
make any representation that the inventions contained in Patent
Rights do not infringe any other patents now held, or that will be held, by others or by Board.

 

3.4        PLx,
by execution hereof, acknowledges, covenants, and agrees that it has not been induced in any way by Board,
System, UTHSC-H
or its employees to enter into this Agreement,
and further warrants and represents that (i) it has conducted sufficient due diligence with respect to all items and issues pertaining
to this Section 3 and all other matters pertaining to this Agreement;
and (ii) PLx has adequate knowledge and expertise, or has
utilized knowledgeable and expert consultants, to adequately conduct the due diligence, and agrees to accept all risks inherent
herein.

 

4.  LICENSE

 

4.1         Board
hereby grants to PLx a royalty-bearing, exclusive
license under Licensed Subject Matter to manufacture, have
manufactured, use, distribute, Sell, offer to Sell,
import, export, lease, loan or otherwise Commercialize
Licensed Products within the Licensed
Territory for use within Licensed Field. This
grant extends to Board’s undivided interest in any
Licensed Subject Matter developed during the term of this
Agreement and jointly owned by Board
and PLx. This grant is subject to any rights
held by the Government of the United States as set forth in Paragraph 3.3, the payment by PLx
to UTHSC-H of all consideration as provided
herein, the timely payment of all amounts due under any Sponsored Research Agreement, and is further subject to the following
rights retained by UTHSC-H and
Board to:

 

		a.	Publish the general scientific findings
                                         from research related to Licensed
                                         Subject Matter subject to the terms of Section 12, Confidential Information;
                                         and

 

		b.	Use Licensed
                                         Subject Matter for non-commercial
                                         research, non-commercial teaching, and other non-commercial educationally-related
                                         purposes.

 

4.2          PLx
may extend the license granted herein to any Affiliate
provided that the Affiliate consents in writing
to be bound by this Agreement to the same extent as PLx.

 

4.3          PLx
may grant sublicenses, marketing and distribution agreements, and any other agreement granting rights (“Sublicenses”)
consistent with this Agreement if PLx
is responsible for the operations of its Sublicensees
to this Agreement as if the operations were carried out
by PLx, including without limitation the payment of royalties
or other consideration whether or not paid to PLx by a
Sublicensee and indemnity provisions equivalent to Section
11. PLx shall deliver to Board
a true and correct copy of each Sublicense granted by PLx,
and any modification or termination thereof, within thirty (30) days after execution, modification, or termination. Should this
Agreement be terminated for any reason, all existing Sublicenses
shall automatically be assigned to Board.

 

    	 	7	 

     

    

 

4.4          PLx
and UTHSC-H agree that PLx completed the following commercial diligence requirements from the Original
Agreement, as amended:

 

		a.	Within thirty (30) months after
                                         the effective date of the Original Agreement, achieved aggregate equity investments
                                         of greater than or equal to two million five hundred thousand dollars ($2,500,000) such
                                         amount included the initial investment of five hundred thousand dollars ($500,000) made
                                         by MediGen Group, LLC;

 

		b.	Within twelve (12) months after
                                         the effective date of the Original Agreement, developed a first Licensed
                                         Product for use in a clinical trial;

 

		c.	Within twelve (12) months after
                                         the effective date of the Original Agreement, completed preclinical development
                                         studies for the purpose of initiating Phase I Clinical Trials;

 

		d.	Within eighteen (18) months after
                                         the effective date of the Original Agreement, submitted an IND application;

 

		e.	Within eighteen (18) months after
                                         the effective date of the Original Agreement, initiated Phase I Clinical
                                         Trials, or its equivalent under §505(b)(2) of the Federal Food, Drug and Cosmetic
                                         Act;

 

		f.	Within thirty-six (36) months after
                                         the effective date of the Original Agreement, initiated Phase II Clinical
                                         Trials;

 

		g.	Within forty-eight (48) months after
                                         the effective date of the Original Agreement, initiated Phase III Clinical
                                         Trials, or its equivalent under §505(b)(2) of the Federal Food, Drug and Cosmetic
                                         Act.

 

4.5          PLx
shall at all times use its best efforts to commercially develop, manufacture or have others manufacture, seek and obtain
any necessary governmental approval for, and actively promote, market,
Sell,
and distribute Licensed Products in the Licensed
Territory in all lawful ways and to the extent commercially reasonable.

 

		4.6	Reasonable commercial diligence shall require that PLx:

 

		a.	On or before January 8, 2012, submit
                                         an NDA for a Licensed Product; and

 

		b.	On or before, January 8,
                                         2013, Sell or offer for Sale a Licensed Product.

 

4.7          The
time periods for milestones 4.6(a) and (b) above will be extended automatically by the amount of time taken by a Regulatory
Authority for its review and approval of an IND
or NDA. PLx
shall notify UTHSC-H in writing and provide
appropriate documentation of such time period(s).

 

    	 	8	 

     

    

 

 

5.  PAYMENTS AND REPORTS

 

5.1          In
consideration of rights granted by Board to PLx
under this Agreement, PLx
will pay Board the following:

 

		a.	An annual, non-refundable, non-creditable
                                         license management fee in the amount of [*] due and payable on each anniversary of the
                                         Effective Date
                                         beginning on the first anniversary; and

 

		b.	A running royalty equal to [*]of
                                         Net Sales
                                         of Licensed Products
                                         comprising Patent Rights and/or Additional Patent Rights and
                                         [*] where Net Sales of Licensed Products consist of only Technology
                                         Rights made or Sold
                                         by PLx, or Affiliates;
                                         and

 

		c.	If the annual running royalty payments
                                         required to be made pursuant to Section 5.1(b) do not aggregate to an amount greater
                                         than or equal to [*], regardless of whether
                                         there are Sales, an additional annual royalty payment in the amount equal
                                         to the difference between [*] and the aggregate running royalty payments actually made
                                         pursuant to Section 5.1(b) for the year, is
                                         due and payable within thirty (30) days
                                         after each anniversary of the Effective Date until this Agreement
                                         is terminated.

 

		d.	PLx and UTHSC-H agree
                                         that PLx completed the following payment requirements from the Original Agreement,
                                         as amended:

 

		i)	[*] upon completion of the first Phase
                                         III Clinical Trial; and

 

		ii)	One hundred eighty one thousand,
                                         two hundred ninety-six dollars ($181,296) for all reasonable, out of pocket expenses
                                         incurred by UTHSC-H for filing, prosecuting, enforcing and maintaining Patent Rights
                                         through October 30, 2002.

 

		e.	Milestone payments, regardless of
                                         whether the milestones are achieved by PLx, an Affiliate, or Sublicensee,
                                         due and payable within thirty (30) days after each corresponding event listed below:

 

		i)	A one-time payment of [*] upon the
                                         first approval by a Regulatory
                                         Authority to Sell
                                         a Licensed Product.
                                         (If PLx’s
                                         total cash assets are less than [*] when the Regulatory
                                         Authority approval milestone payment matures, then such milestone payment
                                         shall be due and paid within [*] after PLx
                                         total cash assets become greater than [*]).

 

		ii)	A one-time payment of [*] upon the
                                         first attainment of total aggregate revenue from the Sale
                                         of all Licensed
                                         Products of [*] ; and

 

		iii)	A one-time payment of [*]upon the
                                         first attainment of total aggregate revenue from the Sale
                                         of all Licensed
                                         Products of [*]; and

 

    	 	9	 

     

    

 

 

		iv)	A one-time payment of [*] upon the
                                         first attainment of total aggregate revenue from the Sale
                                         of all Licensed
                                         Products of [*].

 

		f.	UTHSC-H will invoice PLx
                                         for all actual out-of-pocket expenses incurred by UTHSC-H for filing, prosecuting,
                                         enforcing and maintaining Patent Rights and Additional Patent Rights. The
                                         invoiced amounts will be due and payable by PLx within thirty (30) days after
                                         receipt of UTHSC-H’s invoice.

 

5.2          In
consideration of rights granted by Board to PLx under this Agreement, PLx further agrees to pay Board,
within sixty (60) days after receipt by PLx:

 

		a.	[*] of any consideration received
                                         by PLx from a Sublicensee or assignee with respect to Licensed Subject
                                         Matter for which PLx has not, as of the date such consideration is due, submitted
                                         an NDA to a Regulatory Authority
                                         for a compound designated in such submissions for only over-the-counter Sales;
                                         and

 

		b.	[*] of any consideration received
                                         by PLx from a Sublicensee or assignee with respect to Licensed Subject
                                         Matter for which PLx has submitted an NDA to
                                         a Regulatory Authority for a compound designated in such submission for
                                         only over-the-counter Sales on or before the date such consideration is due; and

 

		c.	[*] of any consideration received
                                         by PLx from a Sublicensee or assignee with respect to Licensed Subject
                                         Matter for which PLx has not, as of the date such consideration is due, received
                                         approval of an NDA by a Regulatory Authority for a compound designated
                                         in such submission for prescription Sales; and

 

		d.	[*] of any consideration received
                                         by PLx from a Sublicensee or assignee with respect to Licensed Subject
                                         Matter for which PLx has received approval of an NDA by a Regulatory
                                         Authority on or before the date such consideration is due for a compound designated
                                         in such submission for prescription Sales.

 

5.3         The
following shall be excluded from the consideration to which payments owed under Section 5.2(a), (b), (c), and (d): (i) consideration
received as the result of any sale of substantially all the assets of business operations of PLx, provided that any resulting
assignee assumes PLx’s obligations under this Agreement with; and (ii)
funding received by PLx for research and development. The consideration under Section 5.2(a), (b), (c), and (d) shall include,
but not be limited to, prepaid royalties, up-front payments, marketing, distribution, franchise, option, license, or documentation
fees, bonus, milestone payments, distributorship fees or advances, and equity securities in sublicensing, including any payment
to PLx of a premium over the market value of such equity securities.

 

5.4         During
the term of this Agreement and for three (3) years thereafter,
PLx agrees to keep complete and accurate records of its
and its Sublicensees’ Sales
and Net Sales
of Licensed Products under the license granted
in this Agreement in sufficient detail to enable the royalties
payable hereunder to be determined. PLx agrees to permit
Board or its representatives, at Board’s
expense, to periodically examine its books, ledgers, and records during regular business hours for the purpose of and
to the extent necessary to verify any report required under this Agreement and payments owed or paid under Section 5.1,
provided that (a) Board will give PLx at least ten (10) days notice of any such examination, and (b) such an examination
may be made only once for any given calendar year. If the amounts due to Board
are determined to have been underpaid by five percent (5%) or greater, PLx
will pay the cost of the examination and accrued interest at the prime rate, as published by The Wall Street Journal
on the quarterly due date for the payment plus three percent (3%).

 

    	 	10	 

     

    

 

 

5.5         Within
60 days after March 31, June 30, September 30, and December 31, beginning immediately after PLx’s
first Sale of a Licensed
Product, PLx shall deliver to Board
a true and accurate written report, even if no payments are due Board,
giving the particulars of the business conducted by PLx
and its Sublicensees, during the preceding three (3) calendar months under this Agreement,
as are pertinent to calculating payments hereunder. This report will include at least:

 

		a.	the accounting methodologies used
                                         to account for and calculate the items included in the report and any differences in
                                         such accounting methodologies used by Licensee since the previous report;

 

		b.	the total quantities of Licensed
                                         Products produced;

 

		c.	the total Sales
                                         separately listed into United States and foreign Sales;

 

		d.	the gross and Net Sales prices;

 

		e.	the calculation of royalties and
                                         amounts payable thereon;

 

		f.	the
                                         total royalties computed and due Board;

 

		g.	all other consideration received
                                         by Licensee relating to Licensed Products from each Sublicensee,
                                         and Affiliate including the types of consideration set forth in Section 5.3 above
                                         and payments; and

 

		h.	all other amounts due UTHSC-H
                                         herein.

 

Simultaneously with the delivery of each
report, PLx shall pay to Board
the amount, if any, due for the period of each report.

 

5.6          PLx
shall deliver to Board a written report summarizing
PLx’s (and any Sublicensee’s)
efforts and accomplishments during the preceding year in diligently Commercializing Licensed
Subject Matter in the Licensed Territory and
PLx’s (and Sublicensee’s)
commercialization plans for the upcoming year. The first of such reports shall be made within six (6) months after the Effective
Date and subsequent reports shall be made within 60 days after each anniversary of the Effective
Date, irrespective of having a first Sale or
offer for Sale.

 

    	 	11	 

     

    

 

5.7         All
amounts payable herein by PLx shall be paid in United States
funds without deductions for taxes, assessments, fees, or charges of any kind, unless such deductions are required by the laws
and regulations of any applicable jurisdiction. When Licensed Product
is Sold for monies other than United States
dollars, the earned royalties first will be determined in the foreign currency in the country in which such Licensed
Products were Sold, and then converted into
equivalent United States funds. The exchange rate will be that rate as reported by The Wall Street Journal on the last
day of the reporting period, and will be quoted in the continental terms method of quoting exchange rates (local currency per
United States dollar). All royalty payments that are not paid by PLx
by the thirty-first (31st) day after each quarterly payment date shall bear interest at the Prime Rate as reported
by The Wall Street Journal. Such interest payments shall be calculated from the quarterly due dates until the payment is
received by UTHSC-H. UTHSC-H
is a tax-exempt organization under the laws of the State of Texas and of the United States and shall be solely responsible
for any taxes that may hereafter be levied upon the payments to Board.
Payments shall be made by check payable to The University of Texas Health Science Center at Houston, and mailed to UTHSC-H
at the address set forth in Section 16.2, or made via electronic funds transfer to: Bank Name: [*********] PLx
is responsible for wire transfer fees. In the event of a wire transfer, PLx
shall promptly notify UTHSC-H in writing of
such transfer.

 

5.8         No
payments due or royalty rates owed under this Agreement
will be reduced as a result of co-ownership of Licensed Subject Matter
by Board and another party, including, but not
limited to, PLx.

 

5.9         Within
fourteen (14) days after the Effective Date, PLx shall make a cash payment to Board in the amount of [*]
in full satisfaction of amounts owed under Section 5.1(c) of the
Original Agreement through January 8, 2010.

 

6.  COMMON STOCK: EQUITY OWNERSHIP AND PLx BOARD RIGHTS

 

6.1          In
further consideration of the rights granted to PLx by Board
under the Original Agreement, PLx has issued
to Board one million fifty thousand shares (1,050,000) fully
paid, fully dilutive, non-assessable shares of its common’s stock.

 

6.2         Board
will be allowed to designate one member of the board of directors of PLx
in accordance with Section 6(a) (i) of the Shareholders Agreement.

 

7.  TERM AND TERMINATION

 

7.1          The
term of this Agreement is from the effective
date of the Original Agreement to the expiration of the last Patent
Rights or Additional Patent Rights.

 

7.2         Any
time after two (2) years from the Effective Date, or at
any time if PLx has not been Actively
Attempting to Commercialize at least one Licensed Product
for the previous six (6) months, Board and UTHSC-H
have the right to terminate the exclusivity of this license in any national political jurisdiction in the Licensed
Territory if PLx, within ninety (90) days after
receiving written notice from UTHSC-H of intended termination
of exclusivity, fails to provide written evidence reasonably satisfactory to UTHSC-H
that PLx or its Sublicensees
has Commercialized or is Actively
Attempting to Commercialize a Licensed Product in such jurisdiction(s). No termination of the exclusivity of
this license in any single national political jurisdiction shall affect the rights of PLx with respect to this license
in any other national political jurisdiction in the Licensed Territory.

 

    	 	12	 

     

    

 

 

7.3         Any
time after three (3) years from the Effective Date, Board
and UTHSC-H have the right to terminate this
license in any national political jurisdiction in the Licensed Territory
if PLx, within ninety (90) days after receiving
written notice from UTHSC-H of intended termination, fails
to provide written evidence satisfactory to UTHSC-H that
PLx or its Sublicensees
has Commercialized or is Actively
Attempting to Commercialize a Licensed Product in such jurisdiction(s). No termination of this license in any
single national political jurisdiction shall affect the rights of PLx with respect to this license in any other national
political jurisdiction in the Licensed Territory.

 

7.4         Subject
to any rights that survive termination, this Agreement
will automatically terminate in its entirety:

 

		a.	upon
                                         PLx becoming
                                         bankrupt or insolvent, or placement of the business of PLx
                                         in the hands of a receiver, assignee, or trustee, whether by voluntary act
                                         of PLx or otherwise;

 

		b.	following sixty (60) days’
                                         written notice, which notice must make reference to this Section, by either party for
                                         a material breach of a material provision of this Agreement,
                                         including the failure by PLx
                                         to make payments (if any are due) or reports, in accordance with the terms
                                         of Section 5 hereunder, unless, before the end of the sixty (60) day period, the party
                                         in material breach has cured the default or breach and so notifies the other party, stating
                                         the manner of the cure; or

 

		c.	following ninety (90) days’
                                         written notice, which notice must make reference to this Section, by either party for
                                         breaches or defaults on any other obligation under this Agreement,
                                         unless, before the end of the ninety (90) day period, PLx
                                         has cured the default or breach and so notifies Board,
                                         stating the manner of the cure; or

 

		d.	at any time by mutual written agreement
                                         between PLx, UTHSC-H
                                         and Board,
                                         and subject to any terms herein which survive termination; or

 

		e.	under the relevant provisions of
                                         Section 7.3, if invoked, but only with respect to the particular jurisdictions for which
                                         PLx or its Sublicensees have not Commercialized or are not Actively
                                         Attempting to Commercialize.

 

		7.5	If this Agreement
is terminated for any cause:

 

		a.	nothing herein will be construed
                                         to release either party of any obligation matured prior to the effective date of the
                                         termination; and

 

		b.	after the effective date of the
                                         termination, PLx
                                         may Sell all Licensed
                                         Products and parts thereto it has on hand at the date of termination, if PLx
                                         pays earned royalties thereon and any other amounts according to the terms
                                         of Section 5; and

 

		c.	PLx
                                         covenants and agrees to be bound by the provisions of Sections 11 (Indemnification),
                                         12 (Use of Board
                                         and UTHSC-H Name),
                                         and 13 (Confidential Information) of this Agreement;
                                         and

 

    	 	13	 

     

    

 

		d.	PLx
                                         grants to Board
                                         a non-exclusive royalty-bearing license with the right to sublicense others
                                         with respect to improvements made by PLx
                                         (including improvements licensed by PLx
                                         from third parties) in the Licensed
                                         Subject Matter. PLx
                                         and Board
                                         agree to negotiate in good faith the reasonable royalty rate for the non-exclusive license.
                                         Board’s
                                         right to sublicense
                                         others hereunder is solely for the purpose of permitting others to develop and
                                         commercialize the entire technology package; and

 

		e.	all data, prototypes, derivatives
                                         of data, designs or materials, and accompanying rights thereto, provided to PLx
                                         by Inventors,
                                         will be returned to UTHSC-H
                                         at PLx’s
                                         expense.

 

8.  INFRINGEMENT

 

8.1          If
PLx becomes aware of any patent held by a third party that
PLx reasonably believes would be infringed by the continued
Sale of Licensed
Products, or by the use of Licensed Products
by its customers, or of the possible infringement by a third party of the Patent
Rights granted hereunder, PLx agrees to promptly
inform Board of same in writing.

 

8.2          PLx,
at its expense, shall enforce any patent exclusively licensed hereunder against infringement by third parties and it is entitled
to retain recovery from such enforcement. PLx agrees to
pay Board royalty, as set forth in Section 5.1 on any monetary
recovery, in excess of its out-of-pocket expenses in enforcing the patent, if the monetary recovery is for damages or a reasonable
royalty in lieu thereof. If PLx does not file suit against
a substantial infringer of a patent within six (6) months of knowledge thereof, then Board
and UTHSC-H, at their sole discretion and expense,
may enforce any patent licensed hereunder on behalf of itself and PLx,
based upon Board’s sole determination that such suit is necessary to protect
Board’s interests with Board retaining
all recoveries from such enforcement and/or reducing the license granted hereunder to non-exclusive.

 

8.3          In
any infringement suit or dispute, the parties agree to cooperate fully with each other. At the request and expense of the party
bringing suit, the other party will permit access to all relevant personnel, records, papers, information, samples, specimens,
etc., during regular business hours.

 

8.4          PLx
may request that Board join the prosecution
of an infringer. If Board agrees, then PLx
and Board shall jointly enforce against infringement
by third parties and shall be entitled to retain any recovery from such enforcement. After deducting PLx’s
and Board’s third-party, documented, unrecovered
reasonable legal expenses incurred exclusively from such suit, any remaining recovery shall be divided on a pro rata percentage
based upon total costs incurred.

 

    	 	14	 

     

    

 

9.  ASSIGNMENT

 

Except
with the sale of substantially all of PLx’s assets to a third party, this Agreement
may not be assigned by PLx without the prior
written consent of Board, which will not be unreasonably
withheld.

 

10.  PATENT MARKING AND MAINTENANCE

 

10.1          PLx
shall permanently and legibly mark all products and documentation manufactured or Sold
by its Affiliates or Sublicensees
pursuant to this Agreement with a patent notice
as may be permitted or required under Title 35, United States Code, or if such marking is not practicable, shall so mark the accompanying
outer box or product insert for Licensed Products accordingly.

 

10.2       Board
shall use reasonable efforts to obtain and maintain Patent
Rights, including payment of maintenance fees and, where appropriate, preparing, filing, and prosecuting patent applications.

 

11.  INDEMNIFICATION

 

11.1        PLx
agrees to hold harmless and indemnify Board,
System, UTHSC-H,
its Regents, officers, employees, and agents from and against any claims, demands, or causes of action whatsoever, or costs of
suit or reasonable attorney’s fees, including without limitation those costs arising on account of any injury or death of
persons or damage to property caused by, or arising out of, or resulting from, the exercise or practice of the license granted
hereunder by PLx, officers, its Affiliates
or their officers, employees, agents or representatives.

 

11.2        PLx
shall, as a condition to any practice under this Agreement,
secure and as a condition to the continued effectiveness of the license granted under this Agreement,
keep in full force and effect product liability insurance providing coverage for PLx,
as its interest may appear, in an amount of not less than one million dollars ($1,000,000).

 

12.  USE
OF BOARD AND UTHSC-H NAME

 

PLx
may not use the name of UTHSC-H, System or Board
without express written consent, except as reasonably necessary to describe this Agreement
and PLx’s rights hereunder or to disclose
their ownership interests in PLx. UTHSC-H and System
may use PLx’s name and logo for annual reports, brochures, website and internal reports without prior consent.

 

    	 	15	 

     

    

 

13.  CONFIDENTIAL
INFORMATION AND PUBLICATION

 

13.1        Board
and PLx each agree that all information contained
in documents marked “confidential” and forwarded to one by the other (i) are to be received in strict confidence,
(ii) used only for the purposes of this Agreement, and
(iii) not disclosed by the recipient party, its agents or employees without the prior written consent of the other party, except
to the extent that the recipient party can establish competent written proof that such information:

 

		a.	was in the public domain at the
                                         time of disclosure;

 

		b.	later became part of the public
                                         domain through no act or omission of the recipient party, it’s employees, agents,
                                         successors or assigns;

 

		c.	was lawfully disclosed to the recipient
                                         party by a third party having the right to disclose it;

 

		d.	was already known by the recipient
                                         party at the time of disclosure;

 

		e.	was independently developed by the
                                         recipient, as evidenced by written documentation; or

 

		f.	is required by law or regulation
                                         to be disclosed

 

13.2        Each
party’s obligation of confidence hereunder shall be fulfilled by using at least the same degree of care with the other party’s
confidential information as it uses to protect its own confidential information. This obligation shall exist while this Agreement
is in effect and for a period of three (3) years thereafter.

 

13.3        UTHSC-H
will submit its manuscript for any proposed publication of research related to Licensed
Subject Matter to PLx at least thirty (30) days
before publication, and PLx shall have up to thirty (30)
days to review and comment upon the publication in order to protect PLx’s
confidential information. Upon PLx’ request, publication
will be delayed for up to sixty (60) days to enable PLx
to secure adequate intellectual property protection of PLx’s
property that would be adversely affected by the publication.

 

14.  PATENTS AND INVENTIONS

 

14.1        If
after consultation with PLx, both parties agree that a
patent application should be filed for Licensed Subject Matter,
Board will prepare and file the appropriate patent applications,
and PLx will pay the cost of searching, preparing, filing,
prosecuting, and maintaining same. If PLx notifies Board
that it does not intend to pay the costs of an application, or if PLx
does not respond or make an effort to agree with Board
on the disposition of rights in the subject invention, then Board
may file an application at its own expense, such invention shall not be included in Patent Rights or Additional
Patent Rights for the purposes of this Agreement, and PLx
will have no rights to such invention. Board
will provide PLx a copy of any patent application for which
PLx has paid the costs of searching, preparing, and filing,
as well as copies of any documents received or filed with the respective patent office during the prosecution thereof. With respect
to any patent applications hereunder for which PLx is obligated
to bear the costs, PLx shall be entitled to select legal
counsel engaged by Board to prepare and prosecute same, subject to the approval of UTHSC-H,
which approval will not be unreasonably withheld or delayed. Prior to PLx’s
declining to pay the costs of searching, preparing, filing, and prosecuting such patent application in accordance with this Section
14, Board and UTHSC-H
shall not offer such invention or discovery to, or discuss such invention or discovery with, any third party.

 

    	 	16	 

     

    

 

14.2       At
the election of Board through UTHSC-H, PLx will either pay patent legal counsel directly for patent expenses
or will reimburse UTHSC-H for such patent expenses. Patent expense payment delinquencies (whether owed directly to patent
legal counsel or to UTHSC-H) will be considered a payment default for purposes of Section 7.4. At its discretion, UTHSC-H
may allow PLx to instruct patent legal counsel directly, provided, that (a) UTHSC-H is copied on all correspondence
regarding Patent Rights or Additional Patent Rights, (b) UTHSC-H will maintain final authority in all decisions
regarding the prosecution and maintenance of the Patent Rights or Additional Patent Rights, (c) UTHSC-H may
revoke this authorization to instruct patent legal counsel directly at any time, and (d) the patent legal counsel remains counsel
to UTHSC-H with an appropriate contract (and shall not jointly represent PLx unless requested by PLx and
approved by UTHSC-H, and an appropriate engagement letter with System and conflict waiver are in effect). The Parties
agree that they share a common legal interest to get valid enforceable patents and that PLx will maintain as privileged
all information received pursuant to any patent application, prosecution and maintenance contemplated by this Section.

 

14.3        In
those cases where an Improvement has creators other than Dr. Lichtenberger, including another System employee, who
is not an Inventor (“Third Party Inventor”), rights to such modification or further development shall
require an inter-institutional agreement between the Third Party Inventor’s employer(s) and UTHSC-H regarding
these matters, in order for exclusive rights to be conveyed under this Agreement; otherwise a separate agreement for such
Third Party Inventor discoveries or inventions between the Third Party Inventor’s employer(s) and PLx
will be necessary if exclusive rights are desired by PLx.

 

15.  ALTERNATE
DISPUTE RESOLUTION

 

Any dispute or controversy arising out
of or relating to this Agreement, its construction, or
its actual or alleged breach, may be decided by mediation. If the mediation does not result in a resolution of such dispute or
controversy, it may be finally decided by an appropriate method of alternate dispute resolution, including without limitation,
arbitration, conducted in the city of Houston, Texas in accordance with the Licensing Agreement Arbitration Rules of the American
Arbitration Association. The arbitration panel will include members knowledgeable in the evaluation of non-steroidal anti-inflammatory
drugs and the use of phospholipids in gastrointestinal disorders. Judgment upon the award rendered may be entered in the highest
court or forum having jurisdiction, state or federal. The provisions of this Section 15 will not apply to decisions on the validity
of patent claims or to any dispute or controversy as to which any treaty or law prohibits such arbitration. The decision of the
arbitration must be sanctioned by a court of law having jurisdiction to be binding upon and enforceable by the parties. The use
of any method of alternative dispute resolution will not be construed by either party in a manner that would adversely affect
the other party’s rights in court. Nothing in this section will prevent one party from resorting to judicial proceedings
if good faith efforts to resolve a dispute have been unsuccessful or if injunctive relief is necessary to prevent serious and
irreparable harm to one party or third parties.

 

    	 	17	 

     

    

 

16.  GENERAL

 

16.1        This
Agreement constitutes the entire and only agreement between
the parties for Licensed Subject Matter and all other prior
negotiations, representations, agreements, and understandings are superseded hereby. No agreements altering or supplementing the
terms hereof may be made except by a written document signed by both parties.

 

Any notice required
by this Agreement shall be in writing and shall be deemed
to have been given upon being placed in the United States mail, postage prepaid, by registered or certified mail, or upon
receipt by the party to be notified if delivered by personal delivery or recognized overnight delivery service (with proof of
delivery), addressed to UTHSC-H or to PLx, as the case may be, at the respective address set forth below:

 

The University of Texas Health Science Center at Houston

 

Office of Technology Management

 

7000 Fannin, Suite 720

 

Houston, Texas 77030

 

or in the case of PLx
to:

 

Mr. Ronald R. Zimmerman

 

PLx
Pharma Inc.

 

8285 El Rio, Suite 130

 

Houston, Texas 77054

 

FAX: 713.842.3052

 

PHONE: 713.842.1249

 

or other addresses as may be given from
time to time under the terms of this notice provision.

 

16.3        PLx
shall comply with all applicable federal, state, and local laws and regulations in connection with its activities pursuant
to this Agreement. PLx understands that the Arms
Export Control Act (AECA), including its implementing International Traffic In Arms Regulations (ITAR), and the Export Administration
Act (EAA), including its Export Administration Regulations (EAR), are some (but not all) of the laws and regulations that comprise
the U.S. export laws and regulations. PLx further understands that the U.S. export laws and regulations include (but are
not limited to): (a) ITAR and EAR product/service/data-specific requirements; (b) ITAR and EAR ultimate destination-specific requirements;
(c) ITAR and EAR end user-specific requirements; (d) Foreign Corrupt Practices Act; and (e) anti-boycott laws and regulations.
PLx will comply with all then-current applicable export laws and regulations of the U.S. Government (and other applicable
U.S. laws and regulations) pertaining to the Licensed Subject Matter (including any associated products, items, articles,
computer software, media, services, technical data, and other information). PLx certifies that it will not, directly or
indirectly, export (including any deemed export), nor re-export (including any deemed re-export) the Licensed Subject Matter
(including any associated products, items, articles, computer software, media, services, technical data, and other information)
in violation of applicable U.S. laws and regulations. PLx will include a provision in its agreements, substantially similar
to this Section, with its Sublicensees, third party wholesalers and distributors, and physicians, hospitals or other healthcare
providers who purchase a Licensed Subject Matter, requiring that these parties comply with all then-current applicable
U.S. export laws and regulations and other applicable U.S. laws and regulations.

 

    	 	18	 

     

    

 

 

16.4        This
Agreement will be construed and enforced in accordance
with the laws of the United States of America and of the State of Texas.

 

16.5        Failure
of Board or PLx
to enforce a right under this Agreement will
not act as a waiver of that right or the ability to later assert that right relative to the particular situation involved.

 

16.6        Headings
are included herein for convenience only and shall not be used to construe this Agreement.

 

16.7        If
any part of this Agreement is for any reason found to be
unenforceable, all other parts nevertheless remain enforceable.

 

16.8        Nothing
in this Agreement shall constitute a waiver of sovereign immunity of Board or UTHSC-H.

 

[REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK]

 

    	 	19	 

     

    

 

IN
WITNESS WHEREOF, parties hereto have caused their duly authorized representatives to execute this Agreement.

 

	BOARD OF REGENTS OF
    THE UNIVERSITY OF TEXAS SYSTEM	 	PLX PHARMA INC.
	 	 	 
	By:	/s/ T. Kevin Dillon	 	By:	/s/ Ronald R. Zimmerman
	 	 	 	 	 
	T. Kevin Dillon

        Executive Vice President, Chief Operating and Financial
        Officer

        The University of Texas Health Science Center at Houston

         
	 	Ronald R. Zimmerman

        President and Chief Executive Officer

	Date:	12/11/2009	 	Date:	12/11/2009
	 	 	 
	Approved as to Content:	 	 
	 	 	 
	By: 	/s/ Peter J. Davies	 	 
	Peter J. Davies, M.D., Ph.D.	 	 
	Executive Vice President,  Research	 	 
	The University of Texas Health Science Center at Houston	 	 
	 	 	 
	Date:	12/11/2009	 	 
	 	 	 
	Read and Understood:	 	 
	By:	/s/ Lenard M. Lichtenberger, Ph.D.	 	 
	Lenard M. Lichtenberger, Ph.D.
 Inventor

                                                   
	 	 
	Date:	12/11/2009	 	 

 

    	 	20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]